CERS
Price
$1.29
Change
-$0.11 (-7.86%)
Updated
Apr 3 closing price
Capitalization
342.62M
27 days until earnings call
VTAK
Price
$0.34
Change
-$0.00 (-0.00%)
Updated
Apr 3 closing price
Capitalization
3.41M
Ad is loading...

CERS vs VTAK

Header iconCERS vs VTAK Comparison
Open Charts CERS vs VTAKBanner chart's image
Cerus
Price$1.29
Change-$0.11 (-7.86%)
Volume$1.33M
Capitalization342.62M
Catheter Precision
Price$0.34
Change-$0.00 (-0.00%)
Volume$33.63K
Capitalization3.41M
CERS vs VTAK Comparison Chart
Loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CERS vs. VTAK commentary
Apr 04, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CERS is a StrongBuy and VTAK is a StrongBuy.

Ad is loading...
COMPARISON
Comparison
Apr 04, 2025
Stock price -- (CERS: $1.29 vs. VTAK: $0.34)
Brand notoriety: CERS and VTAK are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: CERS: 94% vs. VTAK: 26%
Market capitalization -- CERS: $342.62M vs. VTAK: $3.41M
CERS [@Medical Specialties] is valued at $342.62M. VTAK’s [@Medical Specialties] market capitalization is $3.41M. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $8.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CERS’s FA Score shows that 0 FA rating(s) are green whileVTAK’s FA Score has 2 green FA rating(s).

  • CERS’s FA Score: 0 green, 5 red.
  • VTAK’s FA Score: 2 green, 3 red.
According to our system of comparison, VTAK is a better buy in the long-term than CERS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CERS’s TA Score shows that 4 TA indicator(s) are bullish while VTAK’s TA Score has 3 bullish TA indicator(s).

  • CERS’s TA Score: 4 bullish, 4 bearish.
  • VTAK’s TA Score: 3 bullish, 7 bearish.
According to our system of comparison, CERS is a better buy in the short-term than VTAK.

Price Growth

CERS (@Medical Specialties) experienced а -10.42% price change this week, while VTAK (@Medical Specialties) price change was -11.47% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was -4.65%. For the same industry, the average monthly price growth was +1.31%, and the average quarterly price growth was +1.17%.

Reported Earning Dates

CERS is expected to report earnings on May 01, 2025.

VTAK is expected to report earnings on Mar 14, 2023.

Industries' Descriptions

@Medical Specialties (-4.65% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
CERS($343M) has a higher market cap than VTAK($3.42M). CERS YTD gains are higher at: -16.234 vs. VTAK (-25.698).
CERSVTAKCERS / VTAK
Capitalization343M3.42M10,044%
EBITDA-26.34MN/A-
Gain YTD-16.234-25.69863%
P/E RatioN/AN/A-
Revenue156MN/A-
Total Cash65.9MN/A-
Total Debt96MN/A-
FUNDAMENTALS RATINGS
CERS vs VTAK: Fundamental Ratings
CERS
VTAK
OUTLOOK RATING
1..100
6681
VALUATION
overvalued / fair valued / undervalued
1..100
43
Fair valued
26
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9798
PRICE GROWTH RATING
1..100
7864
P/E GROWTH RATING
1..100
1005
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VTAK's Valuation (26) in the Medical Specialties industry is in the same range as CERS (43). This means that VTAK’s stock grew similarly to CERS’s over the last 12 months.

VTAK's Profit vs Risk Rating (100) in the Medical Specialties industry is in the same range as CERS (100). This means that VTAK’s stock grew similarly to CERS’s over the last 12 months.

CERS's SMR Rating (97) in the Medical Specialties industry is in the same range as VTAK (98). This means that CERS’s stock grew similarly to VTAK’s over the last 12 months.

VTAK's Price Growth Rating (64) in the Medical Specialties industry is in the same range as CERS (78). This means that VTAK’s stock grew similarly to CERS’s over the last 12 months.

VTAK's P/E Growth Rating (5) in the Medical Specialties industry is significantly better than the same rating for CERS (100). This means that VTAK’s stock grew significantly faster than CERS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CERSVTAK
RSI
ODDS (%)
Bullish Trend 1 day ago
85%
Bullish Trend 1 day ago
83%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 1 day ago
83%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
84%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
82%
Bullish Trend 1 day ago
80%
Advances
ODDS (%)
Bullish Trend about 1 month ago
78%
Bullish Trend 19 days ago
83%
Declines
ODDS (%)
Bearish Trend 4 days ago
83%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
89%
Aroon
ODDS (%)
Bearish Trend 1 day ago
87%
Bearish Trend 1 day ago
90%
View a ticker or compare two or three
Ad is loading...
CERS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
VTAK
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
GLBIX9.18N/A
N/A
Leuthold Global Institutional
TIERX8.27N/A
N/A
Nuveen International Eq A
GCVIX23.32N/A
N/A
Goldman Sachs Large Cp Val Insghts Instl
RINCX15.26N/A
N/A
Victory RS Science and Technology C
WWNPX157.18N/A
N/A
Kinetics Paradigm No Load

CERS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CERS has been loosely correlated with LAB. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if CERS jumps, then LAB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CERS
1D Price
Change %
CERS100%
-7.86%
LAB - CERS
47%
Loosely correlated
-9.32%
NNOX - CERS
43%
Loosely correlated
-4.89%
OFIX - CERS
40%
Loosely correlated
-4.66%
HBIO - CERS
38%
Loosely correlated
-19.52%
ICUI - CERS
38%
Loosely correlated
+0.85%
More

VTAK and

Correlation & Price change

A.I.dvisor tells us that VTAK and PRPO have been poorly correlated (+27% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VTAK and PRPO's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VTAK
1D Price
Change %
VTAK100%
-2.02%
PRPO - VTAK
27%
Poorly correlated
-7.37%
BLFS - VTAK
25%
Poorly correlated
-5.63%
SGHT - VTAK
25%
Poorly correlated
-0.89%
CSTL - VTAK
25%
Poorly correlated
-4.95%
CERS - VTAK
25%
Poorly correlated
-7.86%
More